Manish Kumar Clinical Trials & Results, Health, Pharma Proff, Pipeline Analysis, Turner Syndrome Therapeutics, Women health

Pipeline Analysis of Turner Syndrome Therapeutics

Turner syndrome is a chromosomal condition, which occurs when one of the two X chromosomes normally found in women is missing or incomplete. The disease alters the growth and development in females. The symptoms can vary among women who have Turner syndrome.

Women with this condition tend to be shorter than average and are usually unable to conceive a child because of an absence of ovarian function. Some other features of this condition are extra skin on the neck (webbed neck), heart defects and kidney problems, puffiness or swelling (lymphedema) of the hands and feet, and skeletal abnormalities.

For more info download the sample report at:
https://www.pharmaproff.com/request-sample/1149

This condition occurs in about one in 2,500 female births worldwide, but is much more common among pregnancies that do not survive to term (miscarriages and stillbirths).

The drug candidates of Turner syndrome disease pipeline include, but are not limited to are Estradiol and Somatropin pegylated. Some of the companies having drugs in the Turner syndrome disease pipeline are Novo Nordisk A/S, GeneScience Pharmaceuticals Co. Ltd., and Polus Inc.

Manish Kumar Clinical Trials & Results, Health, Pharma Proff, Pipeline Analysis, Uterine Fibroids Therapeutics, Women health

Clinical Trials & Results on Uterine Fibroids Therapeutics

Uterine fibroids, also known as leiomyomas or myomas, are non-cancerous growths that develop from the muscle tissue of the uterus. The size, shape, and location of fibroids can vary greatly. They may be present inside the uterus on its outer surface, or within its wall, or attached to it by a stem-like structure.

A fibroid may remain very small for a long time and suddenly grow rapidly, or grow slowly over a number of years. It usually affects women between the age of 30 to 40 years, but can occur at any age.

For more info download the free sample report at: Uterine Fibroids Therapeutics – Pipeline Analysis 2018

Uterine fibroids may have various symptoms, such as change in menstruation, anaemia, abdominal cramps, constipation, pain during sex, rectal pain, and difficulty urinating or frequent urination. It is diagnosed through ultrasonography, hysteroscopy, hysterosalpingography, and sonohysterography. Some medications are known to reduce heavy bleeding and painful periods, caused due to this condition.

The drug candidates in uterine fibroids disease pipeline include, but are not limited to, Elagolix, OBE2109, and Proellex. Some of the companies having drugs in the uterine fibroids disease pipeline are Neurocrine Biosciences Inc., Abbvie Inc., and ObsEva SA.

Manish Kumar Clinical Trials & Results, Pharma Proff, Pipeline Analysis, Wnt Signaling Pathway Inhibitors

Wnt Signaling Pathway Inhibitors to Witness Significant Growth due to Positive Clinical Results in the Coming Years

Wnt signaling pathway plays an important role in embryonic development. The signaling pathway regulates cell-to-cell interaction, accelerates trophoblast development, activates blastocyst, accelerate chorion-allantois fusion and implantation. A wide range of diseases, such as different types of cancer and degenerative diseases can be treated by deregulation of components involved in Wnt/β-catenin signaling pathway. Also, researchers have demonstrated that moderate weakening of Wnt signaling can eliminate its carcinogenic potential. Based on the recent researches, Wnt Signaling Pathway inhibitors have also shown potential in cardiovascular disorders.

According to the research findings, majority of the drug candidates in the pipeline are being developed to be administered by the oral route. It has been observed that oral route of medications is convenient; available in delayed or rapid release formulation; provides improved patient’s compliance; and has less risk of systemic infections. Administration of Wnt Signaling Pathway Inhibitors through oral route has shown promising results in the clinical studies. Also, according to the analysis, maximum number of drugs in the pipeline are being developed as small molecules.

The companies developing Wnt Signaling Pathway inhibitors for the treatment of cancer and degenerative diseases, have shown positive clinical results in the various phases of drug development. For instance, in October 2018, Samumed LLC, announced the topline data from the phase IIb trial SM04690 in knee osteoarthritis, wherein the treatment with SM04690 showed improvement in function, pain, and global scores of patients.

Some of the key players involved in the development of Wnt signaling pathway inhibitors in the late and mid stage include Samumed LLC, Can-Fite BioPharma Ltd., Tactical Therapeutics Inc., Leap Therapeutics Inc., 2X Oncology Inc., Eisai Co. Ltd., and Novartis AG.

For More Information Download the Sample Report At: https://www.pharmaproff.com/request-sample/1210

Manish Kumar Health, Pharma Proff, Tuberous Sclerosis Therapeutics

Tuberous Sclerosis Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results

Tuberous sclerosis, also known as tuberous sclerosis complex, is a genetic disorder characterized by the growth of numerous noncancerous (benign) tumors in many parts of the body.

Download the sample report @ https://www.pharmaproff.com/request-sample/1120

It can occur in the brain, skin, kidneys, and other organs, in some cases leading to significant health problems. The signs and symptoms of the disease vary from person to person. Virtually all affected people have skin abnormalities, including patches of unusually light-coloured skin, areas of raised and thickened skin, and growths under the nails. It can also cause facial angiofibromas, tumors on the face beginning in childhood.

Some affected children have the characteristic features of autism, a developmental disorder that affects communication and social interaction.

The drug candidates of tuberous sclerosis disease pipeline include, but not limited to, cannabidiol, and TAK-935. Novartis AG, GW Pharmaceuticals plc and Takeda Pharmaceutical Company Limited are some of the major companies having drugs in the tuberous sclerosis therapeutics pipeline.

Manish Kumar Health, Pharma Proff, Prurigo Therapeutics Pipeline

Prurigo Therapeutics Pipeline Analysis 2018

Prurigo is a group of skin diseases characterised by intensely pruritic, and difficult to treat. There are two conditions associated with prurigo which includes nodular prurigo and papular prurigo. Nodular prurigo is characterized by symmetrical lesions usually on the distal limbs; while, papular prurigo represents smaller lesions which affect cape area.

Download the sample report at: https://www.pharmaproff.com/request-sample/1017

Prurigo is associated with other skin conditions such as atopic eczema, iron deficiency, thyroid disease, Hodgkin lymphoma, non-Hodgkin lymphoma, pregnancy, chronic renal failure, diabetes, drug abuse and spinal nerve damage. 

Corticosteroids, sedative anti-histamines, antibiotics, emollients, ciclosporin, azathioprine, thalidomide, neuropathic treatments and phototherapy are some of the standard treatments available for the prurigo. 

Trevi Therapeutics Inc. is a key player in the prurigo therapeutics pipeline arena, which is currently developing Nalbuphine ER, a small molecule which acts as an opioid receptor agonist. The company is also evaluating the product for the treatment of prurigo nodularis. Menlo Therapeutics Inc., and Kiniksa Pharmaceuticals Ltd. are some other players having prurigo therapeutics in their pipeline.

Manish Kumar cardiovascular disease, Health, Pharma Proff, Ventricular Arrhythmia Therapeutics

Ventricular Arrhythmia Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results

Ventricular arrhythmia is a cardiovascular disease that is characterized by slow beats (bradycardia) and fast beats (tachycardia). Ventricular arrhythmia generally occurs in the lower chamber of the heart. 

Download the sample report at: https://www.pharmaproff.com/request-sample/1009

Ventricular fibrillation, ventricular tachycardia, and premature ventricular beats are the three types of ventricular arrhythmia observed in the patients. Among these, ventricular fibrillation is the most serious type and is characterized by irregular and uncontrollable beats.

Get the detailed analysis at: https://www.pharmaproff.com/report/ventricular-arrhythmia-therapeutics-pipeline-analysis

Premature ventricular contraction is characterized by irregular heartbeats, in which the ventricles contract too soon. Ventricular tachycardia is a type of arrhythmia in which the ventricles are no longer in control of the SA node. Huya Bioscience International is in the process of developing HBI-3000 as a multi-ion channel blocker for the treatment of ventricular arrhythmia. Also, ARMGO Pharma Inc. is in the process of developing ARM036 as a ryanodine receptor calcium release channel modulator for the treatment of this disease. 

Manish Kumar Galectin Inhibitor Therapeutics, Health, Pharma Proff

Galectin Inhibitor Therapeutics – Pipeline Analysis 2019

Galectins belong to the family of animal lectins and perform function by interacting with cytoplasmic and nuclear proteins, cell-surface and extracellular matrix glycoproteins and glycolipids to modulate signalling pathways. Studies have shown the crucial roles of galectin in cancer as they contribute to tumour cell survival, tumour metastasis, angiogenesis and neoplastic transformation.

Download the sample Report @ https://www.pharmaproff.com/request-sample/1209

Many studies have demonstrated role of galectins in the pathogenesis of various diseases including malignant, fibrotic and inflammatory diseases; hence, emerges as an attractive target for the therapeutic of various diseases. Galectin-3 inhibitors has shown positive clinical results for the treatment of acute lymphoblastic leukemia. Thus, providing several opportunities to the companies for the development of galectin-based therapies for the treatment of multiple human diseases.

Get the detailed analysis @ https://www.pharmaproff.com/report/galectin-inhibitor-therapeutics

Galectin Therapeutics Inc. is in the process of developing GR-MD-02 as a galectin-3 inhibitor for the treatment of fibrosis, cancer and plaque psoriasis. It is also being studied in combination with Yervoy and Keytruda, for the treatment of cancer. GlycoMimetics Inc., and Galecto Biotech AB are some other companies having pipeline of galectin inhibitors.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Manish Kumar Health, Infertility Therapeutics

Infertility Therapeutics  - Pipeline Analysis

Infertility is defined as the biological inability to conceive or contribute to conception, after having regular unprotected sex. According to the data published by the Department of Health and Human Services, approximately 10% to 15% of couples in the U.S. are infertile and have not conceived after at least one year of regular, unprotected sex.

Infertility may have a single cause in one of the partners, or it could be the result of a combination of factors. Some of the causes of infertility are ovulation disorders in women, chemotherapy, radiotherapy, use of illegal drugs, and testicular infections in men.

Risk factors associated with infertility are smoking, alcohol consumption, obesity, eating disorders, over-exercising, inactivity, sexually transmitted infections (STIs), mental stress, and exposure to some chemicals. Ferring International Center S.A. is in the process of developing FE 999310, for the treatment of infertility. Some of the companies having a pipeline of infertility include CellOxess LLC, TocopheRx, and others.

To know more visit @ http://bit.ly/Infertility-Therapeutics